According to the report from Deloitte Access Economics, which was commissioned by Novartis, the annual cost of the debilitating neurological condition that impacts 4.9 million Australians will reach $35.7 billion in 2018. …
Latest Video
New Stories
-
FDA invites submissions to new rapid review priority program
July 25, 2025 - - Latest News -
Pharmac marks 12-month anniversary of funding boost
July 25, 2025 - - Latest News -
AccessCR announces finalists in Consumer Partnerships in Research Awards
July 24, 2025 - - Latest News -
Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close
July 24, 2025 - - Australian Biotech -
Australia on the list of countries to be targeted over pharmaceutical pricing
July 24, 2025 - - Latest News -
Latest trade agreements reveal US focus on resolving longstanding issues
July 24, 2025 - - Latest News -
Sanofi to acquire Vicebio, gaining rights to Queensland discovered technology
July 23, 2025 - - Australian Biotech